Raymond James Financial Services Advisors’s AnaptysBio ANAB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,600	Closed	-$259K	–	2574
2018 Q3	$259K	Buy	+2,600	New	+$216K	﹤0.01%	2365
2018 Q2	–	Sell	-2,500	Closed	-$260K	–	2780
2018 Q1	$260K	Hold	2,500	–	–	﹤0.01%	2111
2017 Q4	$252K	Buy	+2,500	New	+$184K	﹤0.01%	2115

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Raymond James Financial Services Advisors's ANAB Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of AnaptysBio (ANAB) in Q4 2018, closing a stake of 2,600 shares — an estimated $259K sold.

Raymond James Financial Services Advisors first reported a position in ANAB in Q4 2017 and held it in 3 quarters. The position peaked at $260K in Q1 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

Raymond James Financial Services Advisors reported no remaining AnaptysBio position as of Q4 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 2,600 AnaptysBio shares in Q4 2018, an estimated $259K.
Raymond James Financial Services Advisors first reported a position in AnaptysBio in Q4 2017 and held it in 3 quarters.
Raymond James Financial Services Advisors's AnaptysBio position peaked at $260K in Q1 2018.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.